Global Blau Syndrome Market By Type (Treatment, Diagnosis), By Route of Administration (Oral, Parental), By End-User (Hospitals, Diagnostics Centers, Specialty Clinics), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Blau Syndrome Market Introduction:

Blau syndrome is an inflammatory disorder that primarily affects the skin, joints, and eyes. Signs and symptoms begin in childhood, usually before the age of 4. Granulomatous dermatitis which is a form of skin inflammation is one of the earliest signs of Blau syndrome. This condition causes a persistent rash that involves hard lumps or can be scaly, and is generally felt under the skin; this rash is primarily found on the arms, legs, and torso.

Arthritis is also common in patients suffering from Blau syndrome and is characterized as the inflammation of the lining of the joints (synovium). Synovitis causes joint pain and swelling. It begins by affecting the joints of the hands, wrists, feet, and then ankles. The worsening of this condition may lead to the involvement of additional joints, thereby restricting movement by decreasing the range of motion of several joints.

Uveitis causes the inflammation of the middle layer of the eye called the uvea. This condition is common among most Blau syndrome patients. The uvea consists of the iris and its related tissue that underline the sclera. Uveitis causes eye irritation and pain, blurred vision, and photophobia. Blau syndrome majorly occurs due to a single mutation in the nucleotide-binding oligomerization domain containing the 2 (NOD2) gene, which produces proteins responsible for immune responses.

The global Blau syndrome market is segmented on the basis of – type, route of administration, end-user, and region. Listed below is this market’s segmentation:

By Type

• Treatment
• Diagnosis

Route of Administration

• Oral
• Parental
• Others

End-User

• Hospitals
• Diagnostics Centers
• Specialty Clinics
• Others

Key Players:

• Pfizer
• Janssen Pharmaceuticals Inc.
• Salix Pharmaceutical
• Novartis AG
• Mylan N.V.
• Himka Pharmaceuticals PLC
• Oncodesign
• Amgen Inc.
• Abbvie Inc.
• Alkem Labs
• Accord Healthcare
• Zydus Pharmaceuticals
• Centogene AG
• Teva Pharmaceuticals
• among others.

By Region

• North America
  • The US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Korea
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East and Africa
  • GCC
  • Israel
  • South Africa
  • Rest of MEA

Market Dynamics–

Increasing awareness levels concerning Blau syndrome, coupled with the ongoing investments towards the healthcare industry are factors expected to boost the revenue growth prospects for this target market. Unfortunately, lower awareness levels among developing nations, as well as the negative impacts of the ongoing COVID-19 pandemic are factors that are expected to influence this market’s financial trajectory. This pandemic has disrupted various manufacturing processes, the effective distribution and sales of goods, from grocery, produce to medical supplies.

Various nations imposed respective lockdowns in order to slow-down the further contagion. With increasing vaccination drives being held across various nations, respective lockdowns are gradually being relaxed. Manufacturing and sales activities are said to be back on track in the months to follow. These factors are expected to in turn bolstering the revenue growth of the global Blau syndrome market in the process. Moreover, increasing R&D activities to develop a potential cure for this syndrome is also expected to create lucrative opportunities for market players over the forecast period.

Competitive Landscape

Major players in this market are – Pfizer, Janssen Pharmaceuticals Inc., Salix Pharmaceutical, Novartis AG, Mylan N.V., Himka Pharmaceuticals PLC, Oncodesign, Amgen Inc., Abbvie Inc., Alkem Labs, Accord Healthcare, Zydus Pharmaceuticals, Centogene AG, and Teva Pharmaceuticals, among others.

Key Developments:

In 2018, Oprphan Biovitrum AB received approvals from the European Commission for Kineret, a monoclonal antibody that is used for the treatments of Blau Syndrome.

For the Blau Syndrome Market research study, the following years have been considered to estimate the market size: